News & Media

The Severity of Schizophrenia Symptoms Can Be a Significant Predictor of Poor Treatment Outcomes Orlando, Fla., October 26, 2018 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data

PRINCETON, N.J. and Redwood City, Calif. – October 11, 2018 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health (Proteus) today announce the signing of an expanded global collaboration agreement that will strengthen the relationship between the two companies for the further development and commercialization of a portfolio of medicines including the ABILIFY MYCITE®

StartUp Health Closes Second Fund to Invest in Companies Focused on Achieving Health MoonshotsSeptember 25, 2018 — New York, NY & San Francisco, CA — StartUp Health, a global organization dedicated to investing in entrepreneurs working to achieve health moonshots, announced today that it has closed its second fund, raising $31M. Investors include Novartis, Ping An Group, Chiesi

The ABILIFY MYCITE System, the first drug-device combination product to be approved by FDA to track drug ingestion, will be integrated into Magellan Health’s mental health provider network PRINCETON, N.J., – August 30, 2018 – Otsuka America Pharmaceutical, Inc. (Otsuka) announced today that it has signed a Collaboration Agreement to facilitate access to the ABILIFY MYCITE® System to